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ABSTRACT 
Objective:  To describe normative levels of PP13 in first-trimester of pregnancy and determine the 
accuracy of PP13 in predicting preeclampsia and small for gestational age (SGA) infants.   
Methods: We measured PP13 in archived first trimester serum samples from an unselected maternal 
cohort of 2,989 women. Associations of PP13 levels and diagnostic accuracy in predicting adverse 
pregnancy outcomes were assessed using multivariate logistic regression models. Due to inadequate 
number of cases we then conducted a systematic review involving structured search of electronic 
databases and subsequent meta-analysis of predictive accuracy using data from similar studies.  
Results: Overall, 2,678 women were included in the in-house study with 71 (2.7%) preeclampsia 
cases, 5 (0.2%) early-onset preeclampsia (≤34 weeks) cases; and 191 (7.1%) and 41 (1.5%) infants 
SGA<10th and <3rd centile. Median (IQR) normative level of PP13 in unaffected pregnancies was 
53.5 (37.7-71.8) pg/ml. The area under the receiver operating characteristic curve (AUC) for 
multivariate models was 0.72 (95%CI 0.66-0.78) for preeclampsia; 0.82 (95%CI 0.63-0.99) for 
early-onset preeclampsia; 0.73 (95%CI 0.69-0.77) for SGA<10th centile; and 0.83 (95%CI 0.78-
0.88) for SGA<3rd centile. Eight studies were included in the systematic review, normative levels of 
PP13 was assessed in four studies but these were variable; and meta-analysis was performed on 
seven studies. Sensitivity rates of PP13 based on 5% fixed false positive rates were 24%, 45% and 
26% for preeclampsia, for early-onset preeclampsia and SGA, respectively. 
Conclusions: First-trimester PP13, in combination with maternal characteristics and other serum 
biomarkers was inadequate for screening purposes and predicting women at risk.   
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First trimester screening of maternal placental protein 13 for predicting preeclampsia and 
small for gestational age: in-house study and systematic review  
 
INTRODUCTION 
Placental protein 13 (PP13) is a 32-kd dimer protein which was first isolated and characterized in 
1983. [1]  PP13 is one of 56 known placental proteins, is exclusively produced by the placenta and 
facilitates trophoblast invasion and maternal artery remodelling. [2, 3]  Moreover, expression is 
induced by syncytialisation of trophoblast cell lines in vitro suggesting that the expression is 
regulated by terminal differentiation. [2, 4-6]  The presence of PP13 on the surface of the placenta 
indicates that PP13 may have haemostatic and immunobiological functions in the placenta.  In 
support of this, aggregates rich in PP13 are associated with zones of T-cell, neutrophil and 
macrophage accumulation. [2]  Moreover, a lysophospholipase function of PP13 may have a 
possible protective function during implantation and in the maintenance of pregnancy. [4]  
Although these properties have not been explored there is potential for dysregulation of PP13 to 
contribute to multiple complications of pregnancy, such as preeclampsia, where aberrant 
placentation and immunological responses are central to disease pathology. 
 
The strong association of PP13 with the placenta and potential to impact trophoblast function have 
generated much interest in PP13 as a biomarker of diagnostic merit. [7-15]  However, less 
remarkable predictive properties have been reported in recent studies, with some describing a 
potential role of PP13 levels for predicting preeclampsia or small for gestational age (SGA) in 
combination with other biomarkers. [9, 12, 15] Variation in study design, population characteristics, 
numbers of cases and reporting of the diagnostic accuracy of PP13, have made it difficult to 
interpret the clinical significance of these results. [9, 12, 15-19]  The original objective of this study 
was to assess normative levels of PP13 in the first trimester of pregnancy and to examine the 
diagnostic accuracy for predicting adverse pregnancy outcomes in an unselected maternity 
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population. However, due to the discontinuation in the production of the PP13 assay after March 
2011, the analysis was only possible for a small number of cases. Therefore, to increase the 
robustness of our findings we incorporated the results from our in-house study (Schneuer et al, 2012 
[Sch]) and conducted a systematic review and meta-analysis of all relevant studies to: i) assess 
normative levels of PP13 in the first-trimester of pregnancy; and ii) examine the association and 
screening performance of PP13 for preeclampsia and SGA. 
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METHODS 
In-house study 
A prospective cohort study was conducted of women with a singleton pregnancy attending first 
trimester Down syndrome screening between July and October 2006 in New South Wales (NSW), 
Australia. Serum samples were collected by the Pacific Laboratory Medicine Services (PaLMs), an 
aneuploidy screening service in NSW and then archived and stored at -80°C.  Serum samples for 
this study were thawed and PP13 levels were measured by an automated immunoassay system 
(AutoDELFIA® PerkinElmer Inc. Turku, Finland). Laboratory technicians were blinded to 
pregnancy outcomes. Intra-assay and inter-assay coefficients of variation were <11% and the 
reported analytic sensitivity of the immunoassay was 0.11 pg/ml.  
 
Maternal information and first trimester screening results derived from the laboratory database were 
combined via record linkage with women’s corresponding health records from routinely collected 
birth and hospital databases to obtain information on the pregnancy and infant outcomes. Birth 
information was obtained from the Perinatal Data Collection (PDC), a statutory surveillance system 
of all births in NSW of at least 400 grams birth weight, or at least 20 weeks’ gestation.  The PDC 
includes demographic, medical and obstetric information on the mother, labour, delivery and birth 
outcome.  Hospital data were obtained from The Admitted Patient Data Collection (APDC), a 
census of all patient hospital admissions from NSW, with records for both mothers and liveborn 
infants. The APDC includes demographic, clinical and health services information for each 
admission. Probabilistic record linkage of data was conducted independently by the NSW Centre 
for Health Record Linkage. [20] The study was approved by the NSW Population and Health 
Services Research Ethics Committee. 
 
The primary outcomes for this study were preeclampsia, early-onset preeclampsia and small for 
gestational age (SGA). Information on preeclampsia was obtained from the hospital data (ICD10-
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AM O11, O14, O15), based on a diagnosis by the attending clinician. Preeclampsia was defined as 
the onset of hypertension (systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 
mm Hg) from 20 weeks’ gestation onwards accompanied by proteinuria. [21]  Early onset 
preeclampsia was defined as women with preeclampsia requiring delivery at ≤34 weeks gestation .  
SGA was defined as birthweight less than the 10th and 3rd centiles of the distribution for gestational 
age by sex based on Australian birthweight charts. [22]  Key explanatory variables included 
maternal age, parity (nulliparous/ multiparous), smoking during pregnancy, maternal weight 
(kilograms) and previous history of preeclampsia or gestational hypertension. Information on Down 
syndrome screening biomarkers: free beta human chorionic gonadotropin (free β-hCG) and 
Pregnancy Associated Plasma Protein A (PAPP-A) were also available for analysis. Gestational age 
was reported in completed weeks of gestation as determined by the best clinical estimate, including 
early ultrasound (>97%) and date of last menstrual period. [23] 
 
Comparison of maternal characteristics and raw concentrations of PP13 between women with and 
without each clinical outcome was performed using contingency tables, t-test analysis or Wilcoxon-
rank sum test for categorical, normal or non-normally distributed variables, respectively.  PP13 
levels were standardized by gestational age, weight and smoking status, using multiple of the 
median (MoM) as described by Cuckle and Wald. [24]  A logarithmic transformation was used to 
normalize the distribution of PP13 MoM and multivariate logistic regression analysis was 
conducted to assess the association between log PP13 MoM with each pregnancy outcome adjusting 
for significant explanatory variables and other relevant biomarkers.  
 
The area under the receiver operating characteristic curve (AUC) was assessed by a traditional 
academic point system with an AUC result of 1 representing a perfect test, 0.9-<1 an excellent test, 
0.8-<0.9 a good test, 0.7-<0.8 a moderate test, 0.6-<0.7 a poor test and 0.5-<0.6 a test with no 
discriminatory value. [25] For each outcome, we dichotomized women’s specific risk using 
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probability cut-points corresponding to 5% and 10% fixed false positive rates.  We then compared 
the predicted outcome with the observed outcome for all women in the study and calculated  
estimates of predictive accuracy including sensitivity, specificity, positive (PPV) and negative 
predictive value (NPV), likelihood ratios (LR) and diagnostic odds ratios with exact binominal 
confidence intervals. [26] Statistical analyses were performed using SAS software 9.2 (SAS 
Institute Inc., Cary, NC, USA) and P<0.05 values were considered to be statistically significant. 
  
Systematic review and meta-analysis 
Structured searches including all languages were completed in PubMed (1990-April 2012), 
MEDLINE (1950-April 2012), and EMBASE (1966-April 2012) and supplemented by cross-
checking reference lists of relevant publications.  Key search terms used alone or in combination 
included: pregnancy, first trimester, gestational age, placenta, blood supply, physiopathology, 
pregnancy proteins, biological markers, prenatal diagnosis, early diagnosis, galectins/blood, 
LGALS13 protein, and placental protein 13. Searches were limited to humans and females.  
 
The systematic review focused on observational studies (cohort, cross-sectional, and case-control) 
that evaluated the accuracy of PP13 to predict preeclampsia (all or early) or SGA. The inclusion 
criteria for the review were as follows: i) study population included women with singleton 
pregnancies; ii) PP13 was measured in serum or plasma in the first trimester of pregnancy, defined 
as ≤14 weeks gestation or mean specimen collection <14 weeks gestation; and iii) PP13 levels 
measured using the Auto DELFIA assay.  Exclusion criteria included case series or reports; 
guidelines, editorials, abstracts, comments or reviews without original data; animal or in vitro 
studies, or studies examining cell lines or genetic components. 
The abstracts of articles identified from the electronic search were screened and full-text of eligible 
articles reviewed for inclusion by two independent assessors. Characteristics, data extraction and 
quality assessment of studies was conducted by each assessor who completed a standard abstraction 
 8 
sheet.  These were then compared and any discrepancies were resolved through discussion 
consensus. The diagnostic performance of PP13 for study outcomes was examined by extrapolating 
extracted data at relevant PP13 cut-points to create 2x2 contingency tables and calculating 
sensitivity, specificity, PPV, NPV and LR. A bivariate, random effects, meta-regression model was 
used to calculate pooled estimates of sensitivity with 95% confidence intervals (95% CIs) at the 5% 
and 10% fixed false positives rate. Chi-square test was used to asses heterogeneity between studies 
(P<0.05). These analyses were conducted using SAS software 9.2 (SAS Institute Inc., Cary, NC, 
USA). 
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RESULTS 
In-house study 
A total of 2,989 samples were tested before the assay became unavailable. Linked health 
information was available for 2,784 (93.1%) women and we then excluded 106 women whose 
blood sample was taken before 10 or after 14 weeks gestation, had a medical abortion, twin 
pregnancy or an infant with major congenital anomalies. Demographic data and PP13 serum levels 
are described in Table 1. Maternal age was 32.8 (SD 4.6) years, 1216 (45.4%) where nulliparous 
and 159 (6.1%) smoked during pregnancy. There were 71 (2.7%) women diagnosed with 
preeclampsia, including 5 (0.2%) with early-onset; and 191 (7.1%) SGA<10th centile and 41 (1.5%) 
SGA<3rd centile infants. Median PP13 levels for the total population was 52.7 pg/ml (IQR: 37.0-
71.0) and median PP13 MoM was 0.98 (IQR: 0.73-1.32). Compared with unaffected pregnancies, 
median levels of PP13 were significantly lower for women subsequently diagnosed with 
preeclampsia or a SGA infant (Table 1).  
 
Based on univariate AUC results, the predictive performance of PP13 MoM in early pregnancy for 
determining adverse pregnancy outcomes was poor for preeclampsia and fair for SGA (Table 2). 
Performance increased when maternal factors and other serum biomarkers were included; with good 
detection of more severe outcomes, early-onset preeclampsia and SGA<3rd centile (Table 2). Table 
2 also presents diagnostic accuracy of PP13 and highlights that a positive test result from the 
adjusted models using a 5% false positive rate cut-point was associated with 3.5 to 9-fold increased 
risk of adverse pregnancy outcomes. Using a 5% false positive rate cut-point, sensitivity of PP13 in 
predicting preeclampsia and early-onset preeclampsia was 15.5% and 20.4%, respectively. Both 
PPVs were poor, with only 7.7% and 0.7% women with a positive test developing preeclampsia and 
early-onset preeclampsia, respectively. Also, positive LRs highlight that women with low PP13 
levels would be more than three times more likely to be seen in women with, as opposed to women 
without, preeclampsia. Sensitivity of PP13 in predicting SGA<10th and SGA<3rd centile was up to 
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20.4% and 31.7%, respectively, and PPV and LR for SGA infants were slightly better than for 
preeclampsia (Table 2).  The NPV was high for all pregnancy outcomes, particularly for severe 
cases, indicating that women that do not have low concentrations of PP13 in early pregnancy were 
unlikely to have subsequent diagnosis of early-onset preeclampsia or SGA<3rd centile infants 
(Table 2).  
 
Systematic review and meta-analysis 
Electronic searches yielded 198 citations, of which eight were considered to be relevant in addition 
to our in-house study (Figure 1).  One article was omitted as two studies were based on the same 
population and presented similar data, [16, 27] with the article reporting more complete information  
included. [16] Characteristics of the eight included studies are presented in Table 3. Seven studies 
assessed predictive accuracy of PP13 with conflicting results. [Sch][9, 12, 15-18]   
 
Of the 8 studies, only 4 reported raw PP13 concentrations in controls for assessment of normative 
levels in first trimester of pregnancy, [Sch][16, 17, 19] and these were presented in various formats. 
One study reported a PP13 median of 66.6 pg/ml for controls, [16] and another presented medians 
by week of gestation for weeks 11-13; with values of 53.5, 63.1, 65.7 pg/ml, respectively; [19] 
while a study of nulliparous women reported slightly higher levels of PP-13 (77.3 pg/ml). [17] In 
comparison, median level of PP13 among controls in the in-house study was 53.5 (IQR; 37.7-71.8) 
pg/ml for all woman, 54.7 (IQR; 39.8-72.1) pg/ml for nulliparous women and 53.9, 54.0, 52.5 
pg/ml for gestational week 11-13, respectively.[Sch]  
 
Although, a number of the studies found a significant difference in PP13 MoM levels between cases 
and controls for preeclampsia, [Sch][12] early-onset preeclampsia [12, 15, 16] and SGA; [Sch][9] 
three studies found no association between PP13 levels and adverse pregnancy outcomes. [9, 17, 
18] In most studies, diagnostic accuracy of each outcome was determined at fixed cut-points of 
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false positive rates of 5%, 10% and 20%. The corresponding PP13 MoM values at these cut-points 
were not reported in any of the included studies, but were determined by Schneuer et al, 2011 as 
0.46, 0.55 and 0.68; respectively.  
 
Table 4 provides a summary of the PP13 MoM levels, AUC results and overall diagnostic results 
from the meta-analysis. From the studies that reported AUC results, two reported fair results for 
preeclampsia, three reported good results for early-onset preeclampsia and two studies reported no 
discriminative value for predicting these outcomes. The AUC for SGA was good but was only 
reported by the in-house study.  Combined results for sensitivity at 5% (10%) fixed false positive 
rates highlight that PP13 in combination with maternal characteristics and other biomarkers identify  
24% (40%), 45% (56%) and 26% (39%) of pregnancies that will develop preeclampsia, early-onset 
preeclampsia and SGA, respectively. There was no evidence of between-study heterogeneity for 
sensitivity results (Table 4). 
 
DISCUSSION 
Our in-house study highlights that lower serum levels of PP13 in early pregnancy are associated 
with increased risks of women developing preeclampsia and having a SGA infant. However, the 
diagnostic performance of PP13 for preeclampsia and SGA>10th centile, including information on 
maternal factors and other serum biomarkers was only fair, based on AUC analysis. Results 
improved for the more severe adverse pregnancy outcomes of early-onset preeclampsia and 
SGA<3rd centile. The meta-analysis found that of the studies reporting diagnostic performance of 
PP13, results were comparable with the in-house study. Overall results revealed that for a given 5% 
false positive rate, a test including PP13, maternal characteristics and other biomarkers would 
identify around 25% of pregnancies that will develop preeclampsia and SGA and 45% of early-
onset preeclampsia cases.   
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Our in-house study was a large population-based cohort that had corresponding health information 
available for 93% of samples collected using record linkage of birth outcome data with laboratory 
results. Strengths of our in-house study were the assessment of a large sample and unselected 
consecutive cohort of women attending first trimester screening. Record linkage of laboratory to 
birth and hospital data ensured follow up and ascertainment of pregnancy outcomes with only 
minimal missing information. Women with missing health information had similar characteristics 
compared to those included in the study. However, due to the unavailability of the assay it was 
limited by small numbers of severe cases for assessment.  
 
The advantage of the systematic review and meta-analysis was the ability to undertake a combined 
analysis of all relevant studies. Thus, that provided with larger numbers of cases and comprehensive 
assessment of predictive accuracy of PP13. Strengths of the review were that all included studies 
used a similar gestational age window for testing and the same assay (AutoDELFIA) to analyse the 
serum samples. We limited our analysis to this assay as it is reported to be a more robust and 
reproducible, compared with the previous ELISA format, and has greater sensitivity and dynamic 
range. [28] Additionally, the studies include women of varying characteristics and from diverse 
geographical locations. However, results from the review and subsequent meta-analysis may be 
limited as models from each study were adjusted for different maternal characteristics or 
biomarkers and may not be comparable. One of the main issues of the systematic review was the 
variation in findings between the studies. Although, no between-study heterogeneity was found in 
the meta-analysis for each outcome, this is only relevant for the limited studies that reported 
complete accuracy results. Differences in results may also be explained by study sample size, study 
design or representativeness of the clinical population. [29] These studies also had small numbers of 
cases and prevalence of preeclampsia was overestimated, ranging from 4.5 to 18.3%. [9, 15, 16, 19] 
Most of the studies included in the review were nested case-control and hospital-based studies, 
therefore, their population may not be representative for screening purposes. Moreover, all studies 
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used only uncomplicated pregnancies as controls which may be misleading and bias the 
discriminative ability of PP13 in detecting cases versus controls.[29]  There were four prospective 
cohort studies included in the review (including our own), [12, 17, 18][Sch], although one included 
only nulliparous women. [17] The other two studies by Odibo et al 2010 and Di Lorenzo et al 2012 
had more comparable results to the in-house study; [Sch] although, the latter reported no association 
between PP13 and preeclampsia with their results based on a model which includes a range of other 
variables and appears not to reflect the predictive value of PP13. [18]  
 
Variation in normative PP13 levels among controls across different studies also suggests that there 
may be differences in population characteristics. Studies did not report wether women were taking 
preventive treatment for preeclampsia or dietary supplements that may mask the defects in 
endogenous PP13 production.  The manipulation of PP13 levels by anti-oxidants (such as Vitamin 
C) and Non-steroidal Anti-inflammatory Drugs (such as aspirin) would increase the variability of 
the PP13 measurements in this population and limit diagnostic value. However, it is uncertain 
whether this may have altered the results of the studies. [30]   
 
Differences between studies and only fair diagnostic accuracy may also be explained by differences 
in the underlying aetiology of pregnancy outcomes and the biology of PP13. The causes of 
preeclampsia and SGA are heterogeneous and multifactorial and PP13 levels may be affected in 
some phenotypes and not in others. [30] The frequent variation in PP13 levels between studies 
emphasizes the need for a gold standard or established normative levels for comparison, so that 
concentrations from heterogeneous populations can be tested by an independent marker body or be 
compared to a reference range. [30] Detection of PP13 may also be variable based on amounts 
bound to carbohydrates and/or Immunoglobulin E (IgE) bound which could limit access of the 
antibodies in the assay platform to the antigenic site.  Similarly, if the PP13 was shed in 
 14 
syncytiotrophoblast membranes or placental exosomes [31] it may not be as readily measurable as a 
unbound dimeric protein. 
 
In conclusion, although studies of predictive accuracy of PP13 were promising, they were limited 
due to insufficient numbers of cases and accessibility to do further testing. Meta-analysis of studies 
highlight that accuracy of PP13 combined with other maternal information and serum biomarkers is 
inadequate for screening purposes and predicting women at risk. Additional  biomarkers such as 
specific maternal blood mRNA of high placental expression [32] or uterine artery Doppler flow [9, 
12, 16, 17] have been identified as having potential value and may improve accuracy, but it is 
unclear whether this would be significant and further studies exploring these are required.  
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Table 1: Demographic characteristics of in-house study population, NSW Australia[Sch] 
Maternal 
characteristics 
Unaffected  
N= 2423              
n (%) 
Early PE 
N=5 
n (%) 
All PE 
N=71 
n (%) 
SGA (<3rd) 
N=41 
n (%) 
SGA(<10th) 
N=191 
n (%) 
Maternal age (years)  
Mean (SD) 32.8 (4.6) 32.0 (3.4) 32.0 (4.2) 32.7 (5.7) 32.8 (5.3) 
Nulliparous 1057 (43.6) 1 (20.0) 46 (64.8) 27 (65.0) 118 (61.8) 
Smoking 134 (5.5) 0 1 (1.5) 9 (22.0) 24 (12.6) 
Maternal weight (kg) 
Mean (SD) 67.4 (14.5) 68.4 (6.8) 73.5 (16.6) 59.9 (11.1) 61.1 (12.0) 
Preterm birth  
(<37 weeks) 110 (4.5) 5 (100) 16 (22.9) 2 (4.9) 12 (6.3) 
Previous 
hypertension 160 (6.6) 1 (20) 10 (14.1) 4 (9.8) 8 (4.2) 
Infant birthweight(g)  
Mean (SD) 3582 (492) 1264 (482) 3100 (779) 2487 (269) 2686 (365) 
PP13 (pg/ml)  
Median (IQR) 
53.5         
(37.7 - 71.8) 
        44.0           
(20.8 - 52.2) 
  44.0         
(32.4 - 65.8)* 
40.5           
(30.0 - 58.1)* 
42.8             
(32.9 - 58.2)* 
PP13 MoM  
Median (IQR) 
1.00          
(0.74 - 1.33) 
0.87             
(0.42 - 1.03) 
0.87           
(0.70 - 1.27) 
0.80           
(0.54 - 0.93)* 
0.77            
(0.59 – 1.06)*                                        
 
PE: preeclampsia; SGA: Small for gestational age; SD: Standard deviation; IQR: inter-quartile range; *P-value<0.05 compared with unaffected 
pregnancies 
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Table 2: Accuracy of models using PP-13 concentrations in early pregnancy to predict subsequent adverse pregnancy outcomes based on a 
5% false positive rate for in-house study [Sch] 
Diagnostic accuracy 
results  
SGA<10th  
centile (n=191) 
 
SGA<3rd  
centile (n=41) 
Preeclampsia  
(n=71) 
Early-onset  
preeclampsia (n=5) 
 
Univariate Adjusted* 
 
Univariate Adjusted^ Univariate Adjusted# Univariate Adjusted# 
AUC (95% CI)  
0.64  
(0.60 – 0.69) 
0.73  
(0.69 – 0.77)  
0.65  
(0.57 – 0.74) 
0.83  
(0.78 – 0.88) 
0.55 
(0.48 – 0.62) 
0.72  
(0.66 – 0.78) 
0.61  
(0.26 – 0.96) 
0.82  
(0.63 – 0.99) 
Detected cases  19 39  4 13 4 11 2 1 
Sensitivity (95% CI)  
9.9  
(6.1 – 15.1) 
20.4  
(14.9 – 26.8)  
9.8  
(2.7 – 23.1) 
31.7  
(18.1 – 48.1) 
5.6  
(1.6 – 13.8) 
15.5  
(8 – 26) 
40.0  
(5.3 – 85.3) 
20.0  
(0.5 – 71.6) 
Positive predictive 
value (95% CI)  
13.5  
(8.3 – 13.2) 
24.2  
(17.8 – 31.6)  
3.0  
(0.8 – 7.5) 
9.2  
(5 – 15.1) 
3.0  
(0.8 – 7.4) 
7.7  
(3.9 – 13.4) 
1.5 
 (0.2 – 5.3) 
0.7  
(0 – 3.6) 
Negative predictive 
value (95% CI)  
93.1 
 (92 – 94) 
93.8  
(92.8 – 94.7)  
98.5  
(97.9 – 98.9) 
98.9  
(98.4 – 99.2) 
97.4  
(96.7 – 98.0) 
97.6  
(97.0 – 98.2) 
99.9  
(99.6 – 100) 
99.8  
(99.6 – 100) 
Positive likelihood 
ratio  2.0 4.1  1.9 6.3 1.1 3.1 8.0 3.4 
Negative  
likelihood ratio  0.9 0.8  1.0 0.7 1.0 0.9 0.6 0.8 
Diagnostic  
odds ratio (95% CI)  
2.1 
(1.3 – 3.5) 
4.8  
(3.3 – 7.2)  
2.0  
(0.7 – 5.8) 
8.8  
(4.4 – 17.3) 
1.1 
(0.4 – 3.1) 
3.5  
(1.8 – 6.7) 
12.6 
(2.1 – 76.1) 
4.0  
(0.4 – 36.3) 
*Adjusted for parity, smoking, weight, age and β-hCG; ^Adjusted for parity, smoking, weight, age, previous hypertension and PAPP-A; # Adjusted for parity, weight, age, previous hypertension and β-hCG; SGA: small for gestational age 
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Table 3: Characteristics of studies measuring maternal serum placental protein 13 (PP13) concentrations in first trimester 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Studies assessing normative levels of PP-13 in early pregnancy; PE- preeclampsia, SGA- small for gestational age; # In-house study 
  
 
 
 
Reference Location Study Design Participants, study period 
Gestational 
age (weeks) Study outcomes Controls 
Akolekar et al, 
2009* [16] 
Kings College Hospital, 
London, UK  
Nested case-
control study 
Singleton,                          
Mar 2006- Oct 
2008 
11-13+6 48 early PE (<34 weeks)   
416 no complications; and normal   
outcome matched to the cases for 
storage time 
Audibert et al, 
2010* [17] 
CHU Sainte-Justine 
Mother and Child 
University Hospital, 
Montreal, Canada 
Prospective 
cohort study 
Singleton, 
nulliparous  
Nov 2006- June 
2008 
11-13 40 PE 9 early PE (<34 weeks) 833 unaffected pregnancies 
Di Lorenzo et al, 
2012 [18] 
Institute for Maternal 
and Child Health, 
Trieste, Italy 
Prospective 
cohort study  
Singleton,                                 
Oct 2007-Apr 
2009 
11-13+6 25 PE 12  early PE (<34 weeks) 2,047  unaffected pregnancies 
Karagiannis et al, 
2011 [9] 
Kings College Hospital, 
London, UK  
Nested case-
control study 
Singleton,                        
Mar 2006-Sept 
2009 
11-13+6 173 SGA (<5
th centile) 
 
877 no complications, normal outcome, 
matched to case for storage time 
Odibo et al, 2011 
[12] 
Washington University 
School of Medicine, St 
Louis, Missouri, USA 
Prospective 
cohort study  
Singleton,                                 
Dec 2009-Mar 
2010 
11-14 42 PE 12 early PE (<34 weeks) 410 unaffected pregnancies (no PE)  
Schneuer et al, 
2011*# [Sch] 
New South Wales, 
Australia 
Prospective 
cohort study 
Singleton, 
July-Oct, 2006 10-14 
71 PE 
5 early PE (<34 weeks) 
191 SGA (<10th centile) 
41 SGA (<3rd centile) 
2,423 unaffected pregnancies 
Stamatopoulou et 
al, 2010* [19] 
University Hospital 
Schleswig-Holstein, 
Kiel, Germany 
Nested case-
control study 
Oct 1998- April 
2008 11-13
+6 33 PE 15 SGA (<10th centile) 
452 normal pregnancies without adverse 
outcomes, matched for storage time and 
gestational age 
Wortelboer et al, 
2010 [15] 
Wilhelmina Children’s 
Hospital Utrecht, the 
Netherlands 
Nested case-
control study 2004-2006 8-13
+6 88 early PE or HELLP syndrome (<34 weeks) 
480 no complications during pregnancy, 
term, same gage at sample date and 
similar duration of  storage time  
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 Table 4: AUC and meta-analysis of PP13 in predicting adverse pregnancy outcomes 
 
SGA: small for gestational age; *Based on SGA <5th centile; # Based on SGA< 3rd centile; NR: not reported AUC: Area under the receiver operating characteristic (ROC) curve; TP: True positives; FPR: False positive rate; ^ Chi-square P>0.05
Outcome 
Study AUC (95% CI) 
TP/ 
total 
cases 
Sensitivity 
(95% CI) at 5% FPR 
TP/ 
total 
cases 
Sensitivity 
(95% CI) at 10% FPR 
All Preeclampsia      
Audibert et al, 2010 0.52 (0.43 - 0.61) NR  NR  
Di Lorenzo et al, 2012 NR 9/25 
 
13/25 
 
Odibo et al, 2011 0.76 (0.62 - 0.82) 13/42 
 
18/42 
 
Schneuer et al, 2011 0.72 (0.66 - 0.78) 11/71 
 
24/71 
 
Pooled^  
 
 
 
 
Early-onset  
preeclampsia      
Akolekar et al, 2009 0.88 (0.85 - 0.91) 21/48 
 
25/48 
 
Audibert et al, 2010 0.48 (0.27 - 0.70) NR  NR  
Di Lorenzo et al, 2012 NR 7/12 
 
8/12 
 
Odibo et al, 2011 0.85 (0.69 - 1.00) 8/12 
 
8/12 
 
Schneuer et al, 2011 0.82 (0.63 - 0.99) 1/5 
 
3/5  
Wortelboer et al, 2010 NR 40/88 
 
48/88 
 
Pooled^   
 
 
 
SGA      
Karagiannis et al, 2011* NR 43/173 
 
64/173 
 
Schneuer et al, 2011# 0.83 (0.78 - 0.88) 13/41 
 
19/41 
 
Pooled^   
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Figure 1: Flowchart of selection procedure for systematic review of studies of PP13 
predicting adverse pregnancy outcomes 
  198 records identified   
(Pubmed=58; Medline=51; Embase=66; 
Maternity and Infant Care=23)   
 98 papers assessed for eligibility  
  by screening titles and abstracts   
29 full text articles assessed  
for eligibility   
100  duplicate records  
excluded   
  
6 9 records excluded    
Cellular study (n=24)   
Animal study (n=10)   
Genetic study (n=6)    
Not 1st trimester PP13 data (n=4)    
No pregnancy outcome (n=2)   
Not singleton pregnancies (n=1)   
Not original data (n=22)   
  
24  records excluded    
None or insufficient data on PP13  
(n=4)  
Cellular/Genetic data only (n=2)   
PP 13 screening in  3rd  trimester (n=1)   
High  risk  population (n=3)   
Pregnancy outcome not PE/IUGR  
(n=3)  
Used non- modified ELISA method  
(n=8)  
Not original data   (n=2)   
  
  
3 records  
Reference list of included  
studies (n=2) 
In-house study (n=1) 
  
  
  
  
SCREENING 
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ELIGIBILITY 
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8 articles   
Objective #1   
N=4  
  
Objective #2   
N=7 
Results in another included study 
(n=1)   
Figure 1: Flowchart of selection procedure for systematic review of studies of PP13 predicting adverse pregnancy 
outcomes 
